FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.